Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
{{output}}
Although the clinical efficacies of third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as osimertinib in the treatment of non-small cell lung cancer (NSCLC) with EGFR-activating mutations are promising, drug-acquire... ...
